... advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Ticagrelor Prasugrel Antiplatelet therapy...

... decisions must be made weighing the risks of ischemic events and future bleeding. In particular, healthcare providers must carefully balance the effectiveness of antiplatelet therapy in the secondary prevention of coronary events, primarily future spontaneous myocardial infarction and stent thrombosis...

...</sub>Y₁₂ Inhibitors Acute coronary syndrome Antiplatelet therapy Since the publication of the CURE [ 1 ] study in 2001, dual antiplatelet therapy, including aspirin and P 2 Y 12 inhibitors, has become the mainstay of antithrombotic therapy for acute coronary...

...Gilles Lemesle; Guillaume Schurtz; Thibaud Meurice; Olivier Tricot; Nestor Lemaire; Sébastien Caudmont; André Philias; Régis Ketelers; Nicolas Lamblin; Christophe Bauters Background: Clopidogrel use as single antiplatelet therapy (SAPT) has never been evaluated in stable coronary artery disease...

.../daily as well as aspirin (81 mg/daily). After 4 months on dual antiplatelet therapy she expectorated blood when coughing. A lung X-ray and CT scan revealed numerous lung nodules later diagnosed as unclassified pleomorphic and spindle cell malignant solid neoplasm. The patient died following multiple...

...Deng-feng Geng; Mo Liu; Dong-mei Jin; Wei Wu; Jing Deng; Jing-feng Wang Background: Uncertainties still remain in terms of what kinds of patients benefit most from cilostazol-based triple antiplatelet therapy (TAT) after coronary stenting. Methods: We performed a meta-analysis of all relevant...

.... Ticagrelor Clopidogrel Clinical trials Monitoring Antiplatelet therapy References 1. Hamrell MR: Raising suspicions with the Food and Drug Administration: detecting misconduct. Sci Eng Ethics 2010;16:697–704. 2. Pronker E, Geerts BF, Cohen A, Pieterse H: Improving the quality of drug...

... trials Event adjudication Antiplatelet therapy Central adjudication of clinical events in randomized controlled trials represents an attractive but still controversial approach. Delegating such a pivotal uniformed task to the central committee for final assessment of trial results is commonly...

... <50% alone. The influence of RI on ST was not significant in patients with multivessel disease, calcified or bifurcation lesions, and target lesion revascularization. Conclusions: These findings substantiate the importance of long-term antiplatelet therapy for patients with RI after drug-eluting stent...